Research news in clinical context
Sexually Transmitted Infections
; 98(3):237-238, 2022.
Article
in English
| ProQuest Central | ID: covidwho-1788985
ABSTRACT
Correspondence to Prof Stefano Rusconi, DIBIC Luigi Sacco, University of Milan, Milan, Italy;stefano.rusconi@unimi.it Treatment regimens for HIV or Hepatitis C Virus do not need to be altered during Paxlovid administration for COVID-19 Treatment with Paxlovid (nirmatrelvir/ritonavir 300/100 mg two times per day for 5 days) is expected to play an important role in patients with mild-to-moderate COVID-19 who are at risk of disease progression. The change to HPV screening is less likely to miss invasive cancer than previous estimates The move away from combined cytology plus human papillomavirus (HPV) testing to HPV testing alone has raised concerns that cases of cervical cancer may be missed among those with a negative HPV test. Investigators in the USA studied the prevalence of invasive cervical cancer in women with a PAP-positive/HPV-negative cotest where a diagnosis would not have occurred as a consequence of symptoms or clinical examination.
Medical Sciences--Dermatology And Venereology; Infections; Laboratories; Cellular biology; Human immunodeficiency virus--HIV; Sexual behavior; COVID-19 vaccines; Investigations; Severe acute respiratory syndrome coronavirus 2; Black people; Cancer therapies; Condoms; Cervical cancer; Gonorrhea; Human papillomavirus; Medical screening; Hepatitis C; Coronaviruses; Drug dosages; Disease transmission; United States--US
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Type of study:
Prognostic study
Language:
English
Journal:
Sexually Transmitted Infections
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS